Hybridize Therapeutics

Executive Summary

Hybridize Therapeutics is a Netherlands-based biotechnology company focused on developing novel hybridization-based RNA therapeutics for chronic kidney disease (CKD). With a lead program in Phase 2/3 clinical trials, the company aims to address the high unmet need in CKD, which affects 1 in 10 people worldwide and leads to over 1.2 million deaths annually. Their proprietary platform leverages oligonucleotide hybridization to modulate disease-related gene expression, offering a targeted approach to slow disease progression and reduce reliance on dialysis. The company's experienced team and established preclinical proof-of-concept support the potential of their lead candidate. As they advance toward pivotal data readouts, Hybridize Therapeutics represents a promising player in the RNA therapy space, with significant upside potential if clinical success is achieved.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 Top-line Data Readout for Lead Candidate45% success
• TBDFDA/EMA Orphan Drug Designation for Lead Candidate70% success
• H2 2026Potential Strategic Partnership or Licensing Deal55% success